Description

Clinical Evidence

• In Human Physiology, Semax administration significantly increased BDNF levels in the hippocampus, correlating with improved memory performance in both animal and human studies.
• Clinical trials in stroke patients reported faster cognitive recovery and improved neurological outcomes with Semax treatment.
• A 2010 study demonstrated that Semax could prevent learning impairment and neuronal damage under hypoxic and oxidative stress conditions.
• Studies suggest Semax may counteract the effects of chronic stress, enhancing working memory and attention span in fatigued individuals.
• Semax is recognized for its dual action—both protective and performance-enhancing—within the central nervous system.

Potential Side Effects

Semax is well-tolerated in animal and human research. Reported effects are rare and mild:

• Temporary nasal irritation (with intranasal delivery)
• Mild headache or dizziness in sensitive individuals
• No observed tolerance, dependence, or hormonal disruption
• Long-term use in clinical settings has not shown any significant toxicity or endocrine disturbance.

Disclaimer

Semax is for laboratory research use only. It is not approved for human or veterinary use outside of licensed clinical trials. All information provided is based on preclinical and limited clinical research. Proper handling by qualified research professionals is required.